Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms

Conditions:   Atrial Fibrillation;   Arrhythmia
Intervention:   Procedure: Firm ablation for transitional AF rotors
Sponsors:   University of California, San Diego;   Abbott
Not yet recruiting - verified April 2016

Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Other: blood samples
Sponsor:   Hospices Civils de Lyon
Recruiting - verified April 2016

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Apixaban;   Drug: Dabigatran;   Drug: Rivaroxaban
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified April 2016

High Dse Vitamin C in Cardiac Surgery Patients

Conditions:   Disorder of Vitamin C;   Atrial Fibrillation;   Complications Due to Coronary Artery Bypass Graft;   Heart Valve Disease
Interventions:   Drug: Ascorbic Acid;   Drug: Placebo
Sponsor:   Virginia Commonwealth University
Not yet recruiting - verified May 2016

Cryo AF Global Registry

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Medtronic Atrial Fibrillation Solutions
Not yet recruiting - verified April 2016

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

Conditions:   Thoracic Surgery;   Atrial Fibrillation in High Risk Patients
Interventions:   Drug: Amiodarone;   Drug: N-Acetylcysteine;   Drug: Placebo
Sponsors:   Memorial Sloan Kettering Cancer Center;   Washington University School of Medicine;   The Cleveland Clinic;   Vanderbilt University School of Medicine
Recruiting - verified April 2016

Excessive Warfarin Anticoagulation - Causes and Consequences

Condition:   Anticoagulation
Intervention:  
Sponsor:   University of Turku
Recruiting - verified May 2016

Comparison of Circumferential Pulmonary Vein Isolation and Complex Pulmonary Vein Isolation Additional Linear Ablation for Recurred Atrial Fibrillation After Previous Catheter Ablation: Prospective Randomized Trial (CALRA-AF)

Condition:   Recurred Atrial Fibrillation
Interventions:   Procedure: Procedure with circumferential pulmonary vein isolation;   Procedure: Procedure with linear ablation in addiction to pulmonary vein isolation
Sponsor:   Yonsei University
Recruiting - verified April 2016

Catheter Ablation Versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF)

Condition:   Persistent Atrial Fibrillation
Interventions:   Procedure: Thoracoscopic Surgical ablation;   Procedure: Catheter ablation
Sponsors:   Royal Brompton & Harefield NHS Foundation Trust;   National Institute for Health Research, United Kingdom;   Liverpool Heart and Chest Hospital NHS Foundation Trust
Recruiting - verified April 2016

Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.

Conditions:   Atrial Fibrillation;   Stroke
Intervention:   Other: decision aid
Sponsor:   Cristian Baicus
Recruiting - verified April 2016

Rivaroxaban vs Apixaban on Menstrual Blood Loss

Condition:   Venous Thromboembolism
Interventions:   Drug: apixaban;   Drug: rivaroxaban
Sponsors:   Indiana University;   Indiana University Health
Not yet recruiting - verified May 2016

The Effect of Nurse Practitioner Led-Care on Quality of Life in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Other: Nurse Practitioner Led-Care;   Other: Cardiologist Led-Care
Sponsor:   University of Alberta
Not yet recruiting - verified April 2016

Prognostic Biomarkers in Patients With Acute Pericarditis

Condition:   Pericarditis
Intervention:  
Sponsor:   Hippocration General Hospital
Recruiting - verified April 2016

Validation Study of Pulse Wave Velocity and Augmentation Index in Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: SphygmoCor version 7, AtCor Medical, Sydney, Australia
Sponsor:   Onze Lieve Vrouw Hospital
Recruiting - verified April 2016

The Low Voltage Guided Ablation Trail of Persistent Atrial Fibrillation

Condition:   Persistent Atrial Fibrillation
Intervention:   Procedure: radiofrequency ablation
Sponsor:   Mödling Hospital
Recruiting - verified April 2016

Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II

Conditions:   Atrial Fibrillation;   Stroke
Intervention:   Other: ECG screening for atrial fibrillation
Sponsors:   Karolinska University Hospital;   Zenicor Medical Systems
Not yet recruiting - verified April 2016

On-pump Beating Coronary Artery Bypass Grafting by Ventricular Assist

Condition:   Coronary Artery Bypass
Interventions:   Device: left ventricular assist;   Procedure: Biventricular assist
Sponsor:   Henan Institute of Cardiovascular Epidemiology
Recruiting - verified May 2016

Patient Convenience Study (RE-SONANCE)

Conditions:   Atrial Fibrillation;   Stroke
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2016

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: Interrupted apixaban;   Drug: Uninterrupted apixaban
Sponsors:   Harvard Clinical Research Institute;   Bristol-Myers Squibb
Recruiting - verified March 2016

A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension

Conditions:   Hypertension;   Atrial Fibrillation
Intervention:   Other: Standard of care
Sponsor:   Bayer
Active, not recruiting - verified April 2016

Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

Condition:   Non-Valvular Atrial Fibrillation
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed - verified April 2016

A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark

Condition:   Anticoagulation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   University Hospital, Gentofte, Copenhagen
Active, not recruiting - verified May 2016

aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Device: LARIAT + PVI;   Device: Pulmonary Vein Isolation
Sponsor:   SentreHEART, Inc.
Recruiting - verified April 2016

Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Other: PVI-ADT;   Other: PVI+ADT
Sponsors:   VZW Cardiovascular Research Center Aalst;   AZ Sint-Jan AV
Active, not recruiting - verified April 2016

Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Device: Amigo™ Robotic Catheter Manipulation;   Device: Manual Catheter Manipulation
Sponsors:   University of California, San Diego;   Catheter Robotics, Inc.
Recruiting - verified April 2016

Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ACP-196;   Drug: ibrutinib
Sponsor:   Acerta Pharma BV
Recruiting - verified April 2016

The Aortic Surgery Cerebral Protection Evaluation (ACE) Randomized Trial

Condition:   Aortic Aneurysm, Thoracic
Interventions:   Procedure: Axillary artery cannulation;   Procedure: Innominate artery cannulation
Sponsors:   St. Michael's Hospital, Toronto;   London Health Sciences Centre
Recruiting - verified April 2016

Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF

Condition:   Atrial Fibrillation
Interventions:   Procedure: Conventional AF Ablation with PVI;   Procedure: FIRM-guided ablation plus PVI
Sponsor:   Stanford University
Recruiting - verified May 2016

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Duke University;   Bristol-Myers Squibb;   Pfizer
Recruiting - verified December 2015

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Intervention:  
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified May 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified April 2016

Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach

Conditions:   Atrial Fibrillation;   Persistent or Longstanding Persistent Atrial Fibrillation
Intervention:   Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation
Sponsor:   AtriCure, Inc.
Recruiting - verified April 2016

Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Medtronic Atrial Fibrillation Solutions;   IHF GmbH - Institut für Herzinfarktforschung
Recruiting - verified April 2016

Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects

Condition:   Sleep Disorders
Intervention:  
Sponsor:   Itamar-Medical, Israel
Recruiting - verified April 2016

Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.

Condition:   Vasoplegic Syndrome
Interventions:   Drug: Norepinephrine;   Drug: Norepinephrine
Sponsor:   Centre Hospitalier Universitaire, Amiens
Recruiting - verified April 2016

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Dabigatran Etexilate 150mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Pilot Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: Flecainide;   Drug: Sotalol
Sponsors:   Vanderbilt University;   Medtronic
Recruiting - verified April 2016

Clinical Study of the TSP Crosser System for Transseptal Access and Left Atrial Catheter Navigation

Condition:   Atrial Fibrillation
Intervention:   Device: TSP Crosser Transseptal Access System
Sponsors:   Transseptal Solutions Ltd.;   Meditrial Europe Ltd.
Recruiting - verified April 2016

Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease

Condition:   Coronary Disease
Interventions:   Drug: Dabigatran;   Drug: Enoxaparin
Sponsors:   University of Sao Paulo General Hospital;   Fundação de Amparo à Pesquisa do Estado de São Paulo
Completed - verified August 2014

Cryoballoon Ablation for Early Persistent Atrial Fibrillation (Cryo4 Persistent AF)

Condition:   Atrial Fibrillation
Intervention:   Other: Holter monitoring
Sponsor:   Medtronic Atrial Fibrillation Solutions
Recruiting - verified April 2016

Cologne Cardioversion Study

Conditions:   Atrial Arrhythmia;   Heart Failure
Interventions:   Device: Internal Electrocardioversion;   Device: External Electrocardioversion
Sponsors:   Universitätsklinikum Köln;   Medtronic
Recruiting - verified May 2016

AdaptResponse Clinical Trial

Condition:   Heart Failure With Left Bundle Branch Block
Interventions:   Device: aCRT ON;   Device: aCRT OFF
Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
Recruiting - verified April 2016

Early Post-marketing Study of Eliquis (Apixaban)

Condition:   Non-valvular Atrial Fibrillation (NVAF)
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified July 2015

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2016

BiventRicular Pacing in prolongEd Atrio-Ventricular intervaL: the REAL-CRT Study

Condition:   First Degree Atrioventricular Block
Interventions:   Device: Cardiac resynchronization therapy pacemaker;   Device: Dual chamber pacemaker
Sponsor:   Gianluca Botto
Recruiting - verified April 2016

Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: Implantation of LAA closure device
Sponsor:   Occlutech International AB
Recruiting - verified May 2016

Non Invasive Mapping Before Ablation for Atrial Fibrillation.

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Brugmann University Hospital;   Centre Hospitalier Universitaire Brugmann
Active, not recruiting - verified April 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: edoxaban;   Drug: Enoxaparin;   Drug: Warfarin
Sponsors:   Daiichi Sankyo Inc.;   Covance;   Quintiles, Inc.
Active, not recruiting - verified April 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified April 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified April 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified April 2016

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified April 2016

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Condition:   Non-valvular Atrial Fibrillation
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified May 2016

Anticoagulant Utilization Pattern

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Completed - verified April 2016

Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation

Condition:   Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases
Interventions:   Device: cryoballoon ablation system;   Drug: Antiarrhythmic Drugs
Sponsor:   Medtronic Atrial Fibrillation Solutions
Recruiting - verified April 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Condition:   Severe Aortic Stenosis
Interventions:   Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI);   Procedure: Surgical Aortic Valve Replacement (SAVR);   Device: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Sponsor:   Medtronic Cardiovascular
Recruiting - verified April 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Conditions:   Sleep Apnea;   Heart Failure
Intervention:   Device: Adaptive Servo Ventilation
Sponsors:   Toronto Rehabilitation Institute;   Canadian Institutes of Health Research (CIHR);   Philips Respironics
Recruiting - verified April 2016

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Conditions:   Atrial Fibrillation;   Arrhythmia
Interventions:   Device: Left atrial ablation;   Drug: Rate or Rhythm Control Therapy
Sponsors:   Mayo Clinic;   National Heart, Lung, and Blood Institute (NHLBI);   St. Jude Medical;   Biosense Webster, Inc.
Active, not recruiting - verified April 2016

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points